Passage Bio 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A focused 2026 clinical landscape deep dive into NCT07709533, evaluating Paclitaxel + Cisplatin (TP regimen) plus PD-1 inhibitor in Esophageal Squamous Cell Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and developme

A focused 2026 clinical landscape deep dive into NCT07709520, evaluating Danoprevir Sodium in Hepatitis B: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

Lexeo Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A focused 2026 clinical landscape deep dive into NCT07707687, evaluating Eculizumab in Thrombotic Microangiopathies: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

Voyager Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A focused 2026 clinical landscape deep dive into NCT07708545, evaluating Tegoprazan in Peptic Ulcer Hemorrhage: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07707947, evaluating Selumetinib Hydrogen Sulfate in Ependymoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07709312, evaluating Ginkgo Biloba leaves Extract in Rheumatoid Arthritis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07706985, evaluating Nimotuzumab in Papillary thyroid cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07709650, evaluating Concurrent chemotherapy in Cervical Squamous Cell Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

Xenon Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.